Printer Friendly

StemCells grants license to StemCell Technologies to studyneural stem cells.

StemCells, Inc. (Palo Alto, CA) has entered into a long-term license agreement with StemCell Technologies, Inc. (Vancouver, Canada) and additional offices in the United States, France and England. The license agreement authorizes StemCell Technologies to manufacture, use and sell certain proprietary mouse and rat neural stem cells and culture media for all mammalian neural stem cells, for educational and research purposes worldwide. StemCell Technologies will market some of these research products under their established NeuroCult brand name.

"We are very pleased that StemCell Technologies has agreed to take a license for supplying these materials to the research market," said Martin McGlynn, President and CEO of StemCells. "One of the benefits of our extensive patent portfolio is that we are in a position to encourage research on neural stem cells. I believe that this license will help researchers obtain legitimate access to murine stem cells and associated materials. As I have said before, the more we can learn about the ways in which neural stem cells can be used to improve human health, the more potential there is to use stem cells for therapeutic purposes."

"StemCell Technologies is delighted to receive this license from StemCells, Inc," said Dr. Allen Eaves, President and CEO of StemCell Technologies. "Neural stem cell research is an exciting area of study that holds tremendous promise. We firmly believe that our company can make a significant contribution in helping to move this field forward through the timely development and delivery of high quality standardized research tools, as we have done previously for the hematopoietic stem cell field."

StemCells is the owner or exclusive licensee of 38 issued United States patents of which the majority are in the neural stem cell field, as well as numerous issued and pending foreign counterparts. The license covers the research use of cells under ten of the United States patents and their foreign counterparts.

StemCells, Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury.

StemCell Technologies provides highly specialized cell culture media and cell separation products that support and enable medical research in areas such as cancer, hematology, immunology, cell transplantation, gene therapy, and developmental biology. StemCell Technologies' lead product, MethoCult, is the industry standard media for hematopoietic progenitor assays. The company also offers training courses, coordinates a global proficiency testing program for hematopoietic progenitor assays, and provides contract assay services to the biotechnology and pharmaceutical industry.

StemCells, Inc.

COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1CANA
Date:Sep 1, 2003
Previous Article:Protein Design Labs and Genentech extend antibody agreement.
Next Article:Repligen announces district court decision in inventorship dispute with Bristol-Myers Squibb.

Related Articles
CytoTherapeutics acquires stem cell product pipeline
StemCells obtains neural stem cell patent.
StemCells receives United States patent for methods of isolating pancreatic progenitor cells.
Lame claims for embryonic stem-cell research.
Stem Cells files IND with FDA for transplanting human neural brain stem cells.
NIGMS providing $9 million to three Exploratory Centers for Human Embryonic Stem Cell Research.
StemCells gets FDA ok to begin phase I clinical trial to transplant neural stem cells to treat Batten disease.
StemCells receives IRB approval from OHSU to begin Phase I clinical trial in Batten disease.
Ruling in favor of Neuralstem leads to stay of Stemcells lawsuit.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters